Hudson Edge Investment Partners Inc. Purchases 6,395 Shares of Becton, Dickinson and Company $BDX

Key Points

• Hudson Edge Investment Partners Inc. increased its stake in Becton, Dickinson and Company by 21.9%, acquiring an additional 6,395 shares, bringing its total holdings to 35,650 shares valued at approximately $6.14 million.
• In the first quarter, multiple institutional investors, including Saudi Central Bank and Alpine Bank Wealth Management, also purchased stakes in Becton, Dickinson, indicating strong institutional interest, with 86.97% of the company's stock owned by such investors.
• Becton, Dickinson reported positive quarterly earnings, with an EPS of $3.68 beating estimates, and announced a dividend of $1.04 per share, contributing to an annual yield of 2.2%.

Hudson Edge Investment Partners Inc. raised its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 21.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,650 shares of the medical instruments supplier's stock after buying an additional 6,395 shares during the quarter. Hudson Edge Investment Partners Inc.'s holdings in Becton, Dickinson and Company were worth $6,141,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Saudi Central Bank purchased a new stake in Becton, Dickinson and Company in the 1st quarter worth about $26,000. Smallwood Wealth Investment Management LLC bought a new position in Becton, Dickinson and Company during the first quarter worth about $27,000. Alpine Bank Wealth Management purchased a new position in shares of Becton, Dickinson and Company in the first quarter worth about $29,000. Cornerstone Planning Group LLC raised its position in shares of Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 99 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA purchased a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at approximately $31,000. Hedge funds and other institutional investors own 86.97% of the company's stock.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Claire Fraser sold 917 shares of the company's stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares of the company's stock, valued at $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,023 shares of company stock valued at $562,036. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $191.43 on Friday. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The stock has a fifty day moving average of $188.87 and a 200 day moving average of $187.95. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The firm has a market capitalization of $54.87 billion, a price-to-earnings ratio of 34.43, a P/E/G ratio of 1.49 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.28. The firm had revenue of $5.51 billion for the quarter, compared to analysts' expectations of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company's revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the firm posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were given a dividend of $1.04 per share. The ex-dividend date was Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company's payout ratio is presently 74.82%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on BDX shares. Piper Sandler reiterated a "neutral" rating and issued a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Morgan Stanley lifted their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Argus raised their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Finally, Royal Bank Of Canada began coverage on Becton, Dickinson and Company in a report on Thursday, September 25th. They set a "sector perform" rating and a $211.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $205.40.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.